BridgeBio Pharma Inc. (NASDAQ: BBIO) announced new data from its Phase 3 ATTRibute-CM study at Heart Failure 2026, demonstrating additional clinical benefits of acoramidis in treating transthyretin amyloid cardiomyopathy (ATTR-CM).

The data showed acoramidis increased serum transthyretin levels early and reduced intra-individual variability compared to placebo, with both factors independently associated with reduced all-cause mortality risk. Participants with higher achieved serum transthyretin levels and less variable levels experienced the greatest survival benefit.

The drug demonstrated a 41% reduction in outpatient worsening heart failure risk versus placebo, with separation seen within 30 days and sustained through month 30. Even after adjusting for outpatient worsening heart failure, acoramidis reduced mortality and recurrent cardiovascular hospitalization risk by 41%.

In a matching-adjusted indirect comparison with tafamidis, acoramidis showed a 34% reduction in cardiovascular hospitalizations and a 28% hazard reduction in all-cause mortality, with comparable safety profiles between the treatments.

Additional poster presentations showed acoramidis consistently reduced NT-proBNP increases by approximately 50% across participant subgroups and significantly improved heart failure-related health status compared to placebo.

Acoramidis is approved as Attruby in the United States and as BEYONTTRA in Europe, Japan, Switzerland, the United Kingdom, and Brazil. The drug is indicated for treating ATTR-CM in adults to reduce cardiovascular death and cardiovascular-related hospitalization.

The information is based on a company press release statement.